Skip Navigation

COVID-19: We are vaccinating patients ages 12+. Learn more:

Vaccines, Boosters & Additional Doses | Testing | Patient Care | Visitor Guidelines | Coronavirus | Self-Checker | Email Alerts


Philips Respironics issued a recall for some CPAP and BiLevel PAP devices and mechanical ventilators. Learn more.

Chien-Fu Hung, Ph.D.

Headshot of Chien-Fu Hung
  • Associate Professor of Pathology

Research Interests

Gene therapies; cancer vaccines; ovarian cancer immunotherapy; cancer immunology more


Dr. Chien-Fu Hung is an Associate Professor of Pathology and Oncology and a Professor of Gynecology and Obstetrics at the Johns Hopkins University School of Medicine. He is a member of the Johns Hopkins Kimmel Cancer Center. His research focuses on cancer immunology and immunotherapy development. Specifically, he is working to engineer and test novel biologic immunotherapies and fusion proteins with tumor targeting properties. The targeted mechanism of action for these novel therapies is to reverse the immunosuppressive tumor microenvironment and drive anti-tumor immunity.

He received a Young Investigator Award from the Alliance for Cancer Gene Therapy in 2004.

He was elected member, National Academy of Inventors in 2017. more


  • Associate Professor of Pathology
  • Associate Professor of Gynecology and Obstetrics
  • Associate Professor of Oncology

Departments / Divisions

Centers & Institutes



  • Ph.D.; University of Illinois (Urbana-Champaign) (Illinois) (1996)

Research & Publications

Research Summary

Dr. Hung's research has led to the generation of clinical-grade vaccines for HPV-associated precancerous and cancerous lesions. Of special note, two of Dr. Hung's technologies, DNA vaccines based on HSP70 and calreticulin fusion technologies, have also been licensed and are under active development by biotechnology companies. Recently Dr. Hung's lab has utilized annexin V (AnnV) as an immune checkpoint inhibitor and tumor-homing molecule for the treatment of cancer, as AnnV greatly enhances the immunogenicity and antitumor efficacy after chemoradiation.

Additionally, Dr. Hung has developed a novel universal immunotherapeutic molecule (Alb-Flt3L) by harnessing albumin's ability to extend serum half-life and preferential trafficking towards lymph nodes as well as the properties of Flt3L to potently expand cross-presenting DCs. Alb-Flt3L enhances immunological responses mediated by cross-presenting DCs and subsequently generates potent antigen-specific T and B cell responses.

Selected Publications

Kang TH, Park JH, Yang A, Park HJ, Lee SE, Kim YS, Jang GY, Farmer E, Lam B, Park YM, Hung CF: Annexin A5 as an immune checkpoint inhibitor and tumor-homing molecule for cancer treatment. Nat Commun 2020, 11(1):1137

Tseng SH, Park ST, Lam B, Tsai YC, Cheng MA, Farmer E, Xing D, Hung CF: Novel, genetically induced mouse model that recapitulates the histological morphology and immunosuppressive tumor microenvironment of metastatic peritoneal carcinomatosis. J Immunother Cancer 2020, 8(1)

Kang TH, Yang A, Tsai Y, Ferrall L, Hung CF: Targeted tumor coating with antigenic, CTL-recognizable peptides via Annexin A5 chimeric constructs following chemotherapy redirects adaptive CD8+ T cell immunity for tumor clearance. Cell Mol Immunol 2020

Tseng SH, Lam B, Kung YJ, Lin J, Liu L, Tsai YC, Ferrall L, Roden RBS, Wu TC, Hung CF: A novel pseudovirus-based mouse model of SARS-CoV-2 infection to test COVID-19 interventions. J Biomed Sci 2021, 28(1):34

Is this you? Edit Profile
back to top button